Navigation Links
Cynvec to Present at the 11th Annual Shanghai International Forum on Biotechnology and Pharmaceutical Industry
Date:6/2/2009

NEW YORK, June 2 /PRNewswire/ -- Cynvec LLC, a privately held biotechnology company focused on developing novel cancer therapies that harness the apoptotic ability of the sindbis viral vector, today announced that Frank Stonebanks, President and Chief Executive Officer, will make a presentation titled "Cynvec: Breakthrough Oncolytic Viral Vector Therapy with Sindbis" at the 11th Annual Shanghai International Forum on Biotechnology and Pharmaceutical Industry. Mr. Stonebanks' presentation will take place on Wednesday, June 3, 2009 at 10:00 a.m. local time, in Shanghai China. Additional information about the conference can be found at: www.bio-forum.com.

About Cynvec LLC

Cynvec, a privately held biotechnology company, is developing proprietary cancer therapies based on the apoptotic sindbis oncolytic viral vector, a novel technology that targets the over expressed laminin receptor on the surface of many solid tumors without affecting normal cells. Under an exclusive worldwide license from the NYU School of Medicine, Cynvec is developing its lead product, CYN 101, to be used as a single agent or in combination with cytotoxics, monoclonal antibodies, chemotherapeutic agents and radiation. CYN 101 is a replication defective, apoptotic RNA vector that has shown tumor eradication and highly significant survival rates in pre-clinical models of ovarian and pancreatic cancer as both a single agent and in combination with licensed chemotherapies. Cynvec is also developing a companion vector that will provide an in vivo, quantitative, real time cancer diagnostic. Cynvec expects to begin Phase I clinical trials of CYN 101 in the third quarter of 2009. The sindbis vector has demonstrated in vivo efficacy delivering a variety of cytokines directly to tumor sites. Additionally, a screening program is underway to identify small molecules that bind to the laminin receptor,
'/>"/>

SOURCE Cynvec LLC
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cynvec to Present at New York Biotechnology Association 18th Annual Meeting
2. Cynvec to Present at the BIO National Venture Conference
3. Cynvec LLC(SM) to Present at the Cowen and Company 29th Annual Health Care Conference
4. Cynvec LLC(SM) to Present at the Rodman & Renshaw 10th Annual Healthcare Conference on November 11, 2008
5. Cynvec LLC(SM) Appoints Former Johnson & Johnson Executive Frank D. Stonebanks as President and Chief Executive Officer
6. ViroPharma to Present at Two June Healthcare Conferences
7. Cynosure Announces Presentations at Upcoming Investor Conferences
8. BioMarin to Present at the Goldman Sachs Healthcare Conference
9. Orexigen(R) Therapeutics Announces Upcoming Data Presentations at American Diabetes Association and Endocrine Society Annual Scientific Meetings
10. Micromet to Host Conference Call and Webcast to Discuss Blinatumomab Data Presented at EHA on June 8, 2009
11. Data on VIVUS Qnexa To Be Presented During Two Podium Presentations at ADA Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014 Involution Studios , a ... a new infographic, Understanding Ebola . The ... designed, easy to follow informative tool for anyone wanting ... symptoms and prevention. , "As the news has spread ... Ebola outbreak represents not only a healthcare crisis with ...
(Date:10/22/2014)... October 22, 2014 Physicians Choice ... cardiovascular pharmacogenetics menu, which enables healthcare providers to ... With PCLS’s evidence-based results, healthcare providers are better ... their therapy, while minimizing risks for adverse drug ... according to the FDA [1] more than 2.2 ...
(Date:10/22/2014)... 22, 2014 Nuvilex, Inc. (OTCQB: NVLX) – ... people worldwide are living with diabetes, with  that number ... The global market for diabetes treatments is approximately $500 ... worldwide died from pancreatic cancer.  Pancreatic cancer is the ... in the United States , and ...
(Date:10/20/2014)... , Oct. 20, 2014 Mapp ... experimental ZMapp™ antibody therapeutic to fight the Ebola ... difficult and time-consuming the production of pharmaceuticals can ... research publisher said that while some may be ... this compound, those with industry knowledge are well ...
Breaking Biology Technology:Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3
... Inc. (OTC: MSEL) operating under its principal brand ... of visual communications and brand imaging solutions, was awarded " ... 9th Annual American Business Awards Ceremony, in recognition of its ... solid results, despite prevailing economic turbulence. The American ...
... 2011 Amylin Pharmaceuticals, Inc. (Nasdaq: ... present data for its two first-in-class diabetes drugs, ... and its investigational diabetes drug candidates BYDUREON™ (exenatide ... at the 71st Scientific Sessions of the American ...
... 2011 Scientists Drs. Samuel and Elenore Bogoch of BioRadar ... in Replikin Counts of the EHEC lethal strains of E. ... of E. Coli have been studied in laboratories in Germany ... in the public databases. Replikins are subsequences of the genome ...
Cached Biology Technology:Merisel, Inc. Wins Business Turnaround of the Year at the 2011 American Business Awards 2Merisel, Inc. Wins Business Turnaround of the Year at the 2011 American Business Awards 3Merisel, Inc. Wins Business Turnaround of the Year at the 2011 American Business Awards 4Merisel, Inc. Wins Business Turnaround of the Year at the 2011 American Business Awards 5Amylin Pharmaceuticals to Present Promising New Data on the Company's Diabetes Programs at ADA 2011 2Amylin Pharmaceuticals to Present Promising New Data on the Company's Diabetes Programs at ADA 2011 3Amylin Pharmaceuticals to Present Promising New Data on the Company's Diabetes Programs at ADA 2011 4Amylin Pharmaceuticals to Present Promising New Data on the Company's Diabetes Programs at ADA 2011 5Amylin Pharmaceuticals to Present Promising New Data on the Company's Diabetes Programs at ADA 2011 6Amylin Pharmaceuticals to Present Promising New Data on the Company's Diabetes Programs at ADA 2011 7Amylin Pharmaceuticals to Present Promising New Data on the Company's Diabetes Programs at ADA 2011 8Rising Replikin Counts in E. Coli in Germany Since 2005 Preceded Current E. Coli Outbreak 2Rising Replikin Counts in E. Coli in Germany Since 2005 Preceded Current E. Coli Outbreak 3
(Date:10/18/2014)... patients referred for evaluation of suspected genetic conditions, ... 25 percent, including detection of a number of ... disease, according to a study appearing in ... coincide with the American Society of Human Genetics ... or coding regions of thousands of genes simultaneously ...
(Date:10/17/2014)... news release is available in German . ... millions of sperms every day in order to reproduce? And ... are the topic of the latest issue of the research ... 2014). The evolutionary biologist Steven Ramm from Bielefeld University Bielefeld ... it is not unusual for a female to copulate with ...
(Date:10/16/2014)... body. Battles are won, lost or sometimes end ... as tumor dormancy—can last up to 25 years ... poorly understood. , A new computational model ... Professor of Chemistry at Princeton University, may help ... switch to a malignant state. Published today in ...
Breaking Biology News(10 mins):Whole-exome sequencing shows potential as diagnostic tool 2Sperm wars 2Modeling tumor dormancy 2
... top technological universities have come together to form ... brings together these leading engineering-based universities in the ... address global societal issues is through the joint ... top class research in science and technology. ...
... Scientists have completed the first study of microbes that ... the Gulf of Mexico, where conditions may resemble those ... was partially funded by the National Science Foundation (NSF), ... vents spew mud, oil, brine and gases that support ...
... Outreach efforts by the Translational Genomics Research Institute (TGen) ... the second year, TGen will help organize a cancer ... The 2nd annual Fort Defiance Cancer Awareness and Advocacy ... 8:30 a.m.-5 p.m. July 18 at the Navajo Nation ...
Cached Biology News:Global alliance of leading technological universities to address global societal issues 2Better living through chemistry 2Better living through chemistry 3TGen helps promote cancer awareness for vast Navajo Nation 2TGen helps promote cancer awareness for vast Navajo Nation 3
...
Mouse anti-JNK (PT183/185) Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
Acetyl CoA Carboxylase Antibody...
mu Opioid Receptor splice variant Immunogen: Synthetic peptide corresponding to residues K S C M D R G M R N L L P D D G P R Q E of Mu Opioid Receptor. Storage: -20 C, Avoid Freeze/Thaw Cycle...
Biology Products: